These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20888346)

  • 1. Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide.
    Lou J; Smith RJ
    J Theor Biol; 2011 Jan; 268(1):1-13. PubMed ID: 20888346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
    Matthews T; Salgo M; Greenberg M; Chung J; DeMasi R; Bolognesi D
    Nat Rev Drug Discov; 2004 Mar; 3(3):215-25. PubMed ID: 15031735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological fitness of HIV in patients with resistance to enfuvirtide.
    Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
    AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.
    Melby TE; Despirito M; Demasi RA; Heilek G; Thommes JA; Greenberg ML; Graham N
    AIDS; 2007 Nov; 21(18):2537-9. PubMed ID: 18025893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enfuvirtide, the first fusion inhibitor to treat HIV infection.
    Poveda E; Briz V; Soriano V
    AIDS Rev; 2005; 7(3):139-47. PubMed ID: 16302461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfuvirtide: a new class of antiretroviral therapy for HIV infection.
    Leao JC; Frezzini C; Porter S
    Oral Dis; 2004 Nov; 10(6):327-9. PubMed ID: 15533206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The suppression of immune activation during enfuvirtide-based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin-12 and IP-10 during 48 weeks of longitudinal follow-up.
    Carsenti-Dellamonica H; Saïdi H; Ticchioni M; Guillouet de Salvador F; Dufayard Cottalorda J; Garraffo R; Dellamonica P; Durant J; Gougeon ML
    HIV Med; 2011 Feb; 12(2):65-77. PubMed ID: 20500532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.
    Raffi F; Katlama C; Saag M; Wilkinson M; Chung J; Smiley L; Salgo M
    Clin Infect Dis; 2006 Mar; 42(6):870-7. PubMed ID: 16477567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
    J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfuvirtide (Fuzeon): the first fusion inhibitor.
    Williams IG
    Int J Clin Pract; 2003 Dec; 57(10):890-7. PubMed ID: 14712892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of darunavir and enfuvirtide in a pregnant woman.
    Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
    Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.
    Bonjoch A; Negredo E; Puig J; Erkizia I; Puig T; Cabrera C; Ruiz L; Clotet B
    AIDS; 2006 Sep; 20(14):1896-8. PubMed ID: 16954734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.